Further analysis, including data from clinical specimens and the GEPIA database, indicated a correlation between ICAM1 overexpression and adverse clinical outcomes in cervical cancer patients, underscoring its potential as a therapeutic target. This evidence concerns the gene ICAM1 and cervical cancer.